HOLX - Hologic sees prelim Q1 revenue $1.074B exceeds guidance

• Hologic ( NASDAQ: HOLX ) expects to report Q1 total revenues of ~$1.074B, a decrease of 27.0% compared to the prior year period, or 25.1% in constant currency vs. consensus of $970.3M.
• The preliminary results are higher than the company's most recent revenue guidance range of $940M- $990M, which was provided on October 31, 2022 .
• It expects 15.8% organic constant currency growth in diagnostics ex-COVID; 24.5% organic constant currency growth in molecular diagnostics ex-COVID and 14.7% organic constant currency growth in surgical.
• Hologic has not yet completed its financial close processes for the first quarter of fiscal 2023, therefore GAAP financial results for the quarter have not yet been finalized.
• However, the company expects non-GAAP diluted earnings per share to be above the guidance range of $0.80 to $0.90 provided on October 31, 2022 vs. consensus of $0.87.

For further details see: